Merck inks Keytruda deal with Surface Oncology; Rocket Pharmaceuticals gets expedited review of gene therapy for rare pediatric disease
Merck’s cash cow Keytruda has found another partner.
The pharma took the wraps off a collaboration deal on Tuesday to pair …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
